LTBIHIVscreeningmanuscript260816 (1).pdf (476.07 kB)
Latent tuberculosis infection screening and treatment in HIV: insights from evaluation of UK practice.
journal contribution
posted on 2016-11-25, 12:52 authored by Helena A . White, R. F. Miller, A. L. Pozniak, M. C. Lipman, Iain Stephenson, Martin J. Wiselka, Manish PareekLatent TB infection (LTBI) screening and treatment in HIV-positive individuals in the UK is advocated by the British HIV Association (BHIVA) and National Institute for Health and Care Excellence (NICE), although each recommends differing strategies. We undertook an evaluation of UK practice, relating the responses to the local HIV/TB disease burden. 162 of 188 (86%) UK geographical areas responded; only 93/162 (57.4%) offer LTBI testing with considerable heterogeneity in practice, and no difference in HIV/TB burden between areas offering testing and those who do not. Only 33/93 (35.5%) and 6/93 (6.5%) reported full compliance with BHIVA and NICE guidance respectively. A uniform national guideline is required.
Funding
HAW received a Research Award from Gilead/ British HIV Association, (awarded in 2013). This report is independent research supported by the National Institute for Health Research (NIHR Post-Doctoral Fellowship, Dr Manish Pareek, PDF-2015-08-102). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.
History
Citation
Thorax, 2016Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Infection, Immunity and InflammationVersion
- AM (Accepted Manuscript)